Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.19 USD
+0.23 (7.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Radius Exceeds 2018 Financial Guidance, Provides Updates
by Zacks Equity Research
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
by Zacks Equity Research
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
Has Editas Medicine (EDIT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EDIT) Outperforming Other Medical Stocks This Year?
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Editas Medicine (EDIT)
by Kevin Cook
CRISPR gene editing is going to transform the world and this leader just won key patent battles to capitalize
Aerie's Rhopressa Succeeds in Study on Japanese Patients
by Zacks Equity Research
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
by Zacks Equity Research
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
by Zacks Equity Research
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 55.56% and 120.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
by Zacks Equity Research
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $28, marking a +1.97% move from the previous day.
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas Medicine (EDIT) Stock Moves -0.95%: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed the most recent trading day at $25.98, moving -0.95% from the previous trading session.
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.
Top Performing Active ETFs & Tesla's Best-Case Scenario
by Neena Mishra
Neena Mishra talks with COO of ARK Investment Management, the firm behind most innovative ETFs that have consistently delivered excellent performance.
Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why
by Zacks Equity Research
Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
by Zacks Equity Research
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Options Traders Expect Huge Moves in Editas Medicine (EDIT) Stock
by Zacks Equity Research
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.